Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

Published:2019-08-03 Issue:6 Volume:106 Page:1380-1388
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Bruin Gerard¹,Hasselberg Anke¹,Koroleva Irina²³,Milojevic Julie¹,Calonder Claudio¹,Soon Rachel⁴,Woessner Ralph¹,Pariser David M.⁵,Boutouyrie‐Dumont Bruno¹

Affiliation:

1. Novartis Institutes for BioMedical Research Basel Switzerland

2. Novartis Institutes for BioMedical Research Cambridge USA

3. Current address: Rubius Therapeutics Inc. Cambridge Massachusetts USA

4. Novartis Institutes for BioMedical Research East Hanover New Jersey USA

5. Virginia Clinical Research Inc. Norfolk Virginia USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1558

Reference20 articles.

1. T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis

2. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

3. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

4. Biological Products for the Treatment of Psoriasis: Therapeutic Targets, Pharmacodynamics and Disease-Drug-Drug Interaction Implications

5. Chapter 5 Proinflammatory cytokines in CRP baseline regulation

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development;Clinical Pharmacology & Therapeutics;2023-01-17

2. Denosumab: dosing and drug interaction challenges on the path to approval;Overcoming Obstacles in Drug Discovery and Development;2023

3. The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug–Disease Interaction Under Different Clinical Conditions;Clinical Pharmacokinetics;2022-09-05

4. A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling;British Journal of Clinical Pharmacology;2022-06-16

5. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety;Pharmacology & Therapeutics;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3